

INTERIM REPORT

Period from January 2020 to September 2020

Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03

Peptonic Medical AB (publ) org nr 556776-3064

(www.aktietorget.se ticker: PMED)

Group, Lune Group OY incl subsidiary is included from 2020-06-03

2020 THIRD QUARTER (Jul-Sep)

- Net sales of products KSEK 9 260 (1 533)
- Gross profit KSEK 6 228 (692), Gross margin 67% (45%)
- Operating loss KSEK -7 264 (-4 127)
- Loss per share SEK -0.04 (-0.04)

2020 FIRST NINE MONTHS (Jan-Sep)

- Net sales of products KSEK 13 732 (4 014)
- Gross profit KSEK 9 608 (2 262), Gross margin 70% (56%)
- Operating loss KSEK -20 257 (-12 414)
- Loss per share SEK -0.12 (-0.12)

IMPORTANT EVENTS DURING THE PERIOD

- February 13th, 2020, Peptonic Medical AB announced that it has received a purchase order from its Chinese partner *Shijiazhuang Yuanjia Biotechnology Co. Ltd. ("Yuanjia Bio")* for 53,000 units of VagiVital® for delivery in May 2020. The Products are to be used for collecting user experience data and for building brand awareness among gynaecologists and gynaecology clinics across the country.
- February 25th, 2020, Peptonic Medical AB announced that it has submitted a so called 510(k) application to the US Food and Drug Administration (FDA) to obtain approval to market and sell VagiVital® in the USA.
- April 9th, 2020 - Peptonic Medical AB announced that its self-care product VagiVital® will be available for purchase in all eighty LloydsApotek's retail shops in Sweden from May this year
- May 7th, 2020 - Peptonic Medical AB announced that the Company has filed a patent application concerning the use of its self-care vaginal gel VagiVital® for the treatment of vulvar vestibulitis syndrome (VVS).
- May 14th, 2020 - Peptonic Medical AB announced that it has filed a patent application for and intimate wash based on the Company's vaginal gel VagiVital® and a specifically selected oil. The market as well as the number of applications of products for intimate health are growing. And fastest of these the intimate washes, that can generally be divided into soaps and oils. The challenge for an intimate wash is to clean without causing undesired effects in this delicate area of the body. Peptonic has identified a method to meet this challenge by developing an intimate wash based on its gentle and water-based vaginal gel VagiVital® in combination with an oil.
- May 14th, 2020 - Peptonic Medical AB announced that it has entered into an agreement to acquire a majority of the shares in Lune Group Oy ("Lune"), a Finnish company that sells the Lunetteå menstrual cup.
- June 3rd, 2020 - Peptonic Medical AB announced that all conditions for the acquisition pursuant of Lune Group OY to the agreement have been fulfilled and Peptonic has today completed the acquisition of 60 existing shares in Lune. In connection with the completion, the board has resolved on an issue of 12,228,133 new shares against payment in kind to the current shareholders of Lune as payment for the existing shares in Lune. The board has further resolved on a directed issue of 4,787,037 new shares to Vidarstiftelsen resulting in a cash contribution to Peptonic of 7.5 MSEK which will be used as cash payment for newly issued shares in Lune. The share issues have been resolved in accordance with the authorization from the annual general meeting 2019 and in accordance with the terms that were announced through a press release on 14 May 2020.
- June 30th, 2020, the Company announced that the Annual General Meeting resolved to, for the period until the end of the next Annual General Meeting, elect Anna Tenstam and re-elect Hans von Celsing, Leni Ekendahl and Marianne Östlund as Board members. Hans von Celsing was also elected chairman.
- July 7th, 2020 – Peptonic Medical AB announced that it had decided to use the call option to acquire the remaining shares in Lune from the sellers. The purchase price for the shares amount to MEUR 1.2 (approx. MSEK 12.5, exchange rate 10.43 SEK/EUR) and payment shall be made in the form of new shares in Peptonic. The board of directors intends to within shortly resolve on an issue of 7 442 774 new shares against payment in kind to the sellers, subject to the subsequent approval by the general meeting the 28th of July.
- The Extraordinary General Meeting the 28th of July, 2020, approved the acquisition of outstanding shares in Lune Group OY.
- August 14th, 2020 – Peptonic Medical AB announced that it has received a purchase order from its Chinese partner *Shijiazhuang Yuanjia Biotechnology Co. Ltd.* for 106,000 units of VagiVital® for delivery in two shipments – 53,000 units before the end of the year, and 53,000 units during Q1 2021.
- August 27th 2020 – Peptonic Medical AB announced the results of a customer survey that was performed during spring/early summer this year among VagiVital users. It shows great user satisfaction and effective symptom relief. Of the nearly one hundred respondents, that had used VagiVital for one month or longer, 83 per cent reported symptom relief.
- September 3, 2020 - Peptonic Medical AB informed about the results of the latest clinical study with VagiVital®. The objective of this study was to investigate whether, and to what extent, VagiVital® can relieve symptoms associated with vaginal atrophy in women taking aromatase inhibitors (antiestrogens) as part of their cancer treatment. The results show strong relief of the most bothersome symptoms such as vaginal dryness, vaginal itching and pain during sexual intercourse (dyspareunia). In addition, vaginal pH decreased as a result of treatment with VagiVital®. All improvements were statistically significant (p<0.001) and the magnitude of the improvements were at least on the same level as seen in previous clinical studies with VagiVital®.

IMPORTANT EVENTS AFTER THE END OF THE PERIOD

- November 9th 2020 - Peptonic Medical AB announced that the Company has submitted an application for patent protection for the treatment of genital fungal infections and bacterial vaginosis with a modified VagiVital® formulation. The background to this application is i.a. positive results from in vitro studies showing an effective antifungal effect. Women suffering from fungal infections have spontaneously used VagiVital® and reported good results. In the new formulation, the properties that are judged to contribute to the positive treatment effect have been strengthened.
- November 9th 2020 – Peptonic Medical AB announced that it has exercised the option to obtain a loan of 7.5 MSEK from Vidarstiftelsen according to an agreement as signed in May 2020.

From the CEO

The third quarter was eventful in Peptonic. In addition to seeing a rebound in the retail sales of VagiVital in Sweden (after a decline during the second quarter), we can note many events that contributed to the continued growth of the company.

In July, the option to acquire outstanding shares in Lune Group Oy Ltd was exercised, which means that Lune is now a wholly owned subsidiary of Peptonic Medical AB. This gives us more freedom to integrate the companies and thus find and utilize the synergies between them more quickly. The acquisition was completed through payment with Peptonic shares in accordance with the share purchase agreement.

In August, the Company received a new purchase order for VagiVital for China. It comprised 106,000 tubes to be delivered in two batches - the first in November this year and the second in early 2021. The product (VagiVital Daily Care) is a modified version of the medical device to be registered. The difference lies in the labeling, which for VagiVital Daily Care lacks certain medical claims. The product is used in a large study in China (Real World User Experience Study) to collect efficacy data (including e.g. most bothersome symptoms) and user experiences, which will then be used to complement the registration application for the medical device version. Recruitment for the study takes place through local hospital gynecologists and the participants pay for the product themselves. The price the participants pay for the product is heavily discounted compared to the price offered online via VagiVital's on-line webshop in China (www.vagivital.cn). This is to reward those who want to participate in the study. To date, hospitals in about 15 provinces have joined the study and additional hospitals in other provinces will be engaged. A continuous dialogue is conducted with the registration authority (National Medicinal Products Administration, NMPA) to get an indication of how many subjects are required in this study and whether another clinical study is needed (to follow up objective parameters such as the proportion of vaginal superficial cells). Yuanjia estimates that a decision on the issue will come in the first quarter of next year.

At the beginning of the summer, a survey was conducted among VagiVital's customers in Sweden. The result was very positive regarding both perceived symptom relief and whether users are happy to recommend the product to a friend. In addition, important information was obtained about how the product is being used.

The clinical study conducted with VagiVital on cancer patients treated with aromatase inhibitors (so-called anti-estrogen) after a cancer treatment was completed during the summer. The results were reported in September and showed a very good symptom relieving effect regarding the most troublesome symptoms. This is particularly gratifying, as this patient group often has more severe symptoms than the general population. The study primarily measured the change in the symptom of vaginal atrophy that each patient experienced as most bothersome in self-assessment tests. The symptoms associated with vaginal atrophy that were measured included dyspareunia (pain during sexual intercourse), vaginal dryness, vaginal irritation and itching, and dysuria (pain associated with urination). Secondly, the change in vaginal pH was measured as an objective parameter. Patients were treated with one dose of VagiVital® daily for 12 weeks. The results give us further arguments in the dialogue with gynecologists and midwives.

In our opinion, the registration process in the USA is in its final stages. We have had a good dialogue with the registration authority (FDA) throughout the summer and sent in supplementary documentation according to the authority's requests. At present, no new questions have been received from the FDA, which we interpret as a positive sign. In parallel with the registration process, we have evaluated various alternative distribution channels in the USA. Even though no decisions have been made and no agreements have yet been signed, it is clear that we will invest heavily in a launch in the US as soon as the approval is in place.

Sales of VagiVital during the quarter amounted to KSEK 769. In September, the best sales in Sweden per month since launch were recorded, which gives positive vibes for the future. In Finland, sales declined during the summer (and during the worst Covid period), but reached 'normal' levels in September. Orion is our distributor in Finland and buys full batches from us. During the quarter, we therefore had no sales to them, but we follow their end user sales on an ongoing basis. In Norway and Denmark, sales are steadily increasing, even though volumes are still small relative to Sweden and Finland. In addition to sales via the online store, VagiVital has also been sold directly to a number of gynecology clinics in Norway. In England and Hong Kong, sales have not developed as expected. A major reason is the difficulty of posting our ads on social media in these countries. We work with these challenges to find better solutions in the future. A test sale via online store in Germany has begun to investigate the effect of various tools and activities in this market. The tests will probably continue for a while before we are completely satisfied and formally hit the start button.

Net loss for the VagiVital business unit (including the entire parent company's costs) was KSEK -6,601 for the third quarter, including depreciation costs of KSEK -695.

The third quarter was the first full quarter after the acquisition of Lune Group. Sales of menstrual cups and related items amounted to KSEK 8,491, of which approximately 20% were sold in the US market. The result for the quarter was KSEK -672, which is in line with our expectations at the time of the acquisition. A large part of the sale of menstrual cups goes through physical distribution channels (shops, pharmacies, etc.), which have been strongly negatively affected by Covid-19. A major investment is therefore being made to steer an increasing share of sales to online.

During the autumn, we reorganized and formed two business units - 'Business Unit VagiVital' and 'Business Unit Lunette' with Anna Tenstam and Heli Kurjanen, respectively, as responsible business unit heads. In connection with this and the planning for next year, we have also reshaped the brand strategies. This is still work in progress and which we inform about at a later time.

In September, it was announced that the Swedish Economic Crime Agency has initiated an investigation into a serious insider crime due to measures taken by the Company within the framework of a financing arrangement between the Company and a financial player. Representatives of the Company have been summoned for questioning, and in connection with the hearings, have been notified of suspicion. The Company continues to have confidence in its representatives and today makes the assessment that its operations will not be affected. Furthermore, the view of the Company is that the Company's representatives did not commit insider crime. The company and its representatives intend to continue cooperating with the Authority.

Yesterday we announced that we have taken out a loan of SEK 7.5 million from the Vidarstiftelsen. This is in accordance with the agreement entered into in May this year. The loan strengthens our liquidity and the money will primarily be used for marketing, product launches and in-house development of new products. We are very grateful for this support from the Vidarstiftelsen.

So far, the fourth quarter has been characterized by continued investments in marketing and sales, as well as planning for next year. The planning and preparations for the launch of the intimate wash are going according to plan. In addition, the search for new distributors, products and product ideas continues.

We who work in and with Peptonic have great confidence in the direction set for the Company and have high expectations for the future.

Bromma, November 10th, 2020

CEO

Johan Inbarr

COMPANY BRIEF

Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.

VagiVital® is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.

Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (www.spotlightstockmarket.com, ticker: PMED) in Stockholm, Sweden.

For more information: www.peptonicmedical.com

About VagiVital®

VagiVital® is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.

VagiVital® was launched in Sweden as a non-prescription self-care product in July 2018 (see www.vagivital.com).

FINANCIAL INFORMATION

The acquisition of Lune Group OY was completed on 2020-06-03, this report includes their results from and on 2020-06-03 in the consolidated accounts. The balance sheet is consolidated as of 2020-06-30.

When the entire company was acquired in July 2020, no provision has been made for a minority interest.

Revenue - Sales of goods during the third quarter amounted to SEK 9,260 (1,533) thousand. Other operating income for the quarter was SEK 43 (24) thousand. In the first 9 months, sales of goods amounted to SEK 13,732 (4,014) thousand. Other operating income for the period was SEK 70 (59) thousand.

Costs - Costs for the third quarter amounted to SEK -17,133 (-6,379) thousand. The costs for the first nine months were -35,485 (-18,572). During the first nine months, costs for products have been SEK 4,124 (1,752) thousand and market costs have been approximately SEK 14.5 million (including salaries).

Profit - The company's profit after net financial items for the third quarter amounted to SEK -7,273 (-4,825) thousand. For the three quarters, the corresponding result is SEK -20,270 (-15,132) thousand.

Financial position and liquidity - Cash and bank amounted to SEK 25,379 (19,642) thousand as of September 30, 2020. During the quarter, the company received a net SEK 7,195 thousand in newly issued capital via a directed new issue to the Vidar Foundation. External acquisition costs for Lune Group have during the year a net burden on liquidity of SEK 4,090 thousand due to the acquisition.

Shareholders' equity - The company's shareholders' equity as of September 30, 2020 amounted to SEK 81,910 (73,090) thousand, which gives an equity / assets ratio of 92 (96) percent. Equity increased net by SEK 7,195 thousand through the private placement to Vidarstiftelsen.

Liabilities - The company's liabilities, as of September 30, 2020, amounted to SEK 7,320 (2,988) thousand.

Organization - During the period, the average number of employees was 9 (2). At the end of the period, the number of employees was 16 (3). In addition to this, from 2018 there will be a marketing manager and a quality manager hired as consultants, and the accounts are outsourced to an accounting firm. Employees at Lune Group OY, including subsidiaries, refer to a total of 13 employees.

Share - The total number of shares as of September 30, 2020 was 162,911,613 (127,128,306).

INCOME STATEMENT

Peptonic Group		3 mon jul-sep 2020	3 mon jul-sep 2019	9 mon jan-sep 2020	9 mon jan-sep 2019	12 mon jan-dec 2019
KSEK	Note					
Operating income						
Sales of products		9 260	1 533	13 732	4 014	4 408
Other operating income		43	24	70	59	64
Total operating income		9 303	1 557	13 802	4 073	4 472
Operating expenses						
Cost of goods		-3 032	-841	-4 124	-1 752	-1 825
Other external expenses	1	-8 255	-3 544	-19 380	-11 239	-17 041
Personnel costs		-4 330	-1 299	-8 041	-3 496	-6 475
Depreciation		-915	-695	-2 381	-2 085	-2 855
Other operating costs		-35	0	-133	0	-198
Total operating expenses		-16 567	-6 379	-34 059	-18 572	-28 394
Operating loss		-7 264	-4 822	-20 257	-14 499	-23 922
Net financial income/expense		9	-3	-13	-633	-587
Loss before taxes		-7 255	-4 825	-20 270	-15 132	-24 509
Taxes		-18	0	-14	0	0
Adjustment for minority share of the result		0	0	0	0	0
Net loss for the period		-7 273	-4 825	-20 284	-15 132	-24 509

BALANCE SHEET

Peptonic Group		30-sep	30-sep	31-dec
KSEK	Note	2020	2019	2019
Assets				
Non-Current assets				
Intangible assets	2	54 890	54 751	54 252
Tangible assets	3	1 705	0	0
Financial assets		10	0	0
Total non-current assets		56 606	54 751	54 252
Current assets				
Stock		5 683	679	594
On going fund raising		0	0	0
Other receivbles		412	768	945
Tax receivable		0	0	0
Prepaid expenses and accrued income		1 151	238	176
Liquid assets		25 379	19 642	35 984
Total current assets		32 624	21 327	37 699
Total assets		89 231	76 078	91 951
Equity and liabilities				
Equity				
Ristricted equity				
Share capital		16 477	12 713	13 813
Ongoing right issues		0	0	0
Development Cost Fund		12 032	14 538	12 600
Non- restrictes equity		0	0	0
Share premiun reserv non-restricted		184 926	161 105	182 006
Profit or loss brought forward		-108 718	-100 134	-98 196
Net loss for the period		-22 807	-15 132	-24 509
Minority share of equity		0	0	0
Total equity		81 910	73 090	85 714
Current liabilities				
Liabilities interest bearing		3 616	938	1 974
Trade payables		140	0	0
Other payables		214	252	495
Prepaid income and accrued expenses		3 351	1 798	3 768
Total current liabilities		7 320	2 988	6 237
Total equity and liabilities	4	89 231	76 078	91 951

NOTE

Accounting principles

This interim report has been prepared in accordance with the Annual Accounts Act (Chapter 9. Interim Report) and the Swedish Accounting Standards Board's general advice, BFNAR 2012:1 Annual Report and consolidated (K3-rules).

Note 1 – Related-party transactions

Group/Peptonic Medical AB

During the period companies represented by members of the Board of Directors were contracted as consultants. Board member Anna Tenstam is hired as consultant and responsible for the market area VagiVital. Total compensation for consultancy services amounted to SEK 665 (103) thousand and is related to business development services. All transactions between related parties are based on market conditions. No other key executives or their immediate family members have been directly or indirectly involved in any business transaction with the Company that is or was unusual in its character or terms and conditions and took place during the period.

	2020	2019	2019
KSEK	Jan-Sep	Jan-Sep	Jan-Dec
Consulting fees Board of Directors	665	103	125
Total	665	103	125

Note 2 – Intangible assets (KSEK)

Capitalized patent and development costs are estimated to result in future revenues for the Group. From 2019 they are depreciated at 5% per annum. Which corresponds to the estimated life of the commercial rights.

Peptonic Group	30-sep 2020	30-sep 2019	31-dec 2019
Capitalized development costs			
Accumulated acquisition value			
Opening balance	49 457	48 922	48 922
Sold out and Other disposals	0	0	0
Capitalizations during the period	2 617	263	535
	52 074	49 185	49 457
Accumulated depreciation value	-2 473	0	0
Depreciation of the year	-1 973	-1 854	-2 473
	-4 446	-1 854	-2 473
Net booked amount at end of period	47 628	47 331	46 984
Patents och licenses			
Accumulated acquisition value			
Opening balance	7 803	7 626	7 626
Sold out and Other disposals	0	0	0
Capitalizations during the period	223	177	177
	8 026	7 803	7 803
Depreciation			
Accumulated depreciation value	-535	-152	-152
Depreciation of the year	-229	-231	-383
	-764	-383	-535
Net booked amount at end of period	7 262	7 420	7 268
Total intangible assets	54 890	54 751	54 252

Note 3 - Tangible fixed assets

Group

The Group has activated tools to produce products.

Note 4 – Equity and liabilities

Group

There is a small interest-bearing debt at SEK 140 Thousand in the Group.

KEY FIGURES

Peptonic Group	9 mon jan-jun 2020	9 mon jan-jun 2019	12 mon jan-dec 2019	12 mon jan-dec 2018
Sales goods, KSEK	13 732	2 481	4 408	383
Gross profit sales goods, KSEK	9 608	1 570	2 583	283
Gross margin, %	70%	63%	59%	74%
Operating profit, KSEK	-20 257	-9 695	-23 992	-14 381
Return on equity,%	-32	-31	-35	-26
Equity ratio,%	92	96	93	80
Earnings per share, SEK	-0.12	-0.12	-0.18	-0.17
Liquidity per share, SEK	0.16	0.15	0.26	0.13
Equity per share, SEK	0.50	0.57	0.62	0.64
Share price per closing, SEK	2.54	2.05	1.89	0.50
Share price/Equity per share, SEK	5.05	3.57	3.05	0.78
Total shares	162 911 613	127 128 306	138 128 306	86 028 600

Parent company Peptonic Medical AB

FINANCIAL INFORMATION

Revenue - Sales of goods during the third quarter amounted to SEK 769 (1,533) thousand. Other operating income for the quarter was SEK 16 (24) thousand. For the first 9 months, sales of goods amounted to SEK 3,657 (4,014) thousand. Other operating income for the same period was SEK 32 (59) thousand.

Costs - Costs for the third quarter amounted to SEK -7,385 (-6,379) thousand. The costs for the first 9 months were -22,671 (-18,572). During the 9 months, costs for products have been SEK 1,587 thousand and market costs have been SEK 9,329 thousand.

Profit - The company's profit after net financial items for the third quarter amounted to SEK -6,601 (-4,825) thousand. For the 9 months, the corresponding result is SEK -18,983 (-15,132) thousand.

Financial position and liquidity - Cash and bank as of September 30, 2020, amounted to SEK 11,651 (19,642) thousand. During the quarter, the company received a net SEK 7,195 thousand in newly issued capital via a directed new issue to the Vidar Foundation. The acquisition of Lune Group OY has charged liquidity with SEK 11,285 thousand.

Shareholders' equity - The company's shareholders' equity as of September 30, 2020 amounted to SEK 106,440 (73,090) thousand, which gives an equity / assets ratio of 92 (96) percent. Equity increased by SEK 31,678 thousand through the non-cash acquisitions of Lune Group OY and by SEK 7,195 thousand through the private placement to the Vidar Foundation.

Liabilities - The company's liabilities, as of September 30, 2020, amounted to SEK 3,834 (2,988) thousand.

Organization - During the period, the average number of employees was 3 (2). At the end of the period, the number of employees was 3 (3). In addition to this, there are two hired consultants on the market side and one hired quality manager, and the accounts are outsourced to an accounting firm.

Share - The total number of shares as of September 30, 2020 was 162,911,613 (127,128,306).

INCOME STATEMENT

Peptonic Medical AB

KSEK	Note	3 mon jul-sep 2020	3 mon jul-sep 2019	9 mon jan-sep 2020	9 mon jan-sep 2019	12 mon jan-dec 2019
Operating income						
Sales of products		769	1 533	3 657	4 014	4 408
Other operating income		16	24	32	59	64
Total operating income		785	1 557	3 689	4 073	4 472
Operating expenses						
Cost of goods		-188	-841	-1 587	-1 752	-1 825
Other external expenses	1	-4 378	-3 544	-13 759	-11 239	-17 041
Personnel costs		-2 089	-1 299	-5 107	-3 496	-6 475
Depreciati		-695	-695	-2 085	-2 085	-2 855
Other ope		-35	0	-133	0	-198
Total operating expensses		-7 385	-6 379	-22 671	-18 572	-28 394
Operating loss		-6 600	-4 822	-18 982	-14 499	-23 922
Net financial income/expense		-1	-3	-1	-633	-587
Loss before taxes		-6 601	-4 825	-18 983	-15 132	-24 509
Taxes		0	0	0	0	0
Net loss for the period		-6 601	-4 825	-18 983	-15 132	-24 509

BALANCE SHEET

Peptonic Medical AB

KSEK	Note	30-sep 2020	30-sep 2019	31-dec 2019
Assets				
Non-Current assets				
Intangible assets	2	53 677	54 751	54 252
Tangible assets	3	42 752	0	0
Financial assets		0	0	0
Total non-current assets		96 429	54 751	54 252
Current assets				
Stock		1 204	679	594
On going fund raising		0	0	0
Other receivbles		443	768	945
Tax receivable		0	0	0
Prepaid expenses and accrued income		547	238	176
Liquid assets		11 651	19 642	35 984
Total current assets		13 845	21 327	37 699
Total assets		110 274	76 078	91 951
Equity and liabilities				
Equity				
Ristricted equity				
Share capital		16 291	12 713	13 813
Ongoing right issues		0	0	0
Development Cost Fund		12 032	14 538	12 600
Non- restrictes equity		0	0	0
Share premium reserv non-restricted		219 805	161 105	182 006
Profit or loss brought forward		-122 705	-100 134	-98 196
Net loss for the period		-18 983	-15 132	-24 509
Total equity	3	106 440	73 090	85 714
Current liabilities				
Liabilities interest bearing		1 863	938	1 974
Trade payables		140	0	0
Other payables		0	252	495
Prepaid income and accrued expenses		1 831	1 798	3 768
Total current liabilities		3 834	2 988	6 237
Total equity and liabilities	4	110 274	76 078	91 951

Note 1 – Related-party transactions

Peptonic Medical AB

During the period companies represented by members of the Board of Directors were contracted as consultants. Board member Anna Tenstam is hired as consultant and responsible for the market area VagiVital. Total compensation for consultancy services amounted to SEK 665 (103) thousand and is related to business development services. All transactions between related parties are based on market conditions. No other key executives or their immediate family members have been directly or indirectly involved in any business transaction with the Company that is or was unusual in its character or terms and conditions and took place during the period.

KSEK	2020 Jan-Sep	2019 Jan-Sep	2019 Jan-Dec
Consulting fees Board of Directors	665	103	125
Total	665	103	125

Note 2 – Intangible assets (KSEK)

Capitalized patent and development costs are estimated to result in future revenues for the company. From 2019 they are depreciated at 5% per annum. Which corresponds to the estimated life of the commercial rights.

Peptonic Medical AB	30-jun 2020	30-jun 2019	31-dec 2019
Capitalized development costs			
Accumulated acquisition value			
Opening balance	49 457	48 922	48 922
Sold out and Other disposals	0	0	0
Capitalizations during the period	1 286	263	535
	50 743	49 185	49 457
Accumulated depreciation value	-2 473	0	0
Depreciation of the year	-1 854	-1 854	-2 473
	-4 327	-1 854	-2 473
Net booked amount at end of period	46 416	47 331	46 984
Patents och licenses			
Accumulated acquisition value			
Opening balance	7 803	7 626	7 626
Sold out and Other disposals	0	0	0
Capitalizations during the period	224	177	177
	8 027	7 803	7 803
Depreciation			
Accumulated depreciation value	-535	-152	-152
Depreciation of the year	-231	-231	-383
	-766	-383	-535
Net booked amount at end of period	7 261	7 420	7 268
Total intangible assets	53 677	54 751	54 252

Note 3 - Tangible fixed assets

Parent Company

The acquisition of the shares in Lune Group OY is capitalized under this item. It is a long-term acquisition. In June 2020, 60 percent of the shares were acquired through a non-cash issue. In addition, additional shares were acquired through a private placement of 750,000 Euros. Through this acquisition, the company has a total share of the company of 68% as of 30 June 2020. During the month of July, the entire company was acquired through a non-cash issue on the remaining outstanding shares.

As of September 30, 2020, a total of SEK 42,752 thousand has been capitalized for the acquisition. Of these, the non-cash issue refers to a value of SEK 31,678 thousand and the private placement to Lune Group OY SEK 7,911 thousand. Capitalized acquisition costs relate to SEK 3,163 thousand. Liquidity has been charged with SEK 11,285 thousand for the acquisition, a directed new issue in connection with the acquisition has raised a net SEK 7,195 thousand. In total, net liquidity was charged with SEK 4,090 thousand due to the acquisition.

Note 4 – Equity and liabilities

Parent company

There is no interest-bearing debts.

This interim report has not been reviewed by the Company's auditors.

The Board of Directors and the CEO certifies that the interim report gives a fair overview of the business, position and profit or loss of the Company.

FINANCIAL CALENDER

Year end report, 2020

February 26th 2021

Stockholm, November 10th, 2020

Hans von Celsing, Chairmen of the Board

Anna Tenstam, Board member

Marianne Östlund, Board member

Leni Ekendahl, Board member

Johan Inborr, CEO

For more information please contact:

Johan Inborr, CEO PEPTONIC medical AB. Phone: +46 708 853 893

This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10th November 2020.

Note: This document has been prepared in both Swedish and English. The Swedish version shall govern in case of differences between the two documents. The document contains certain statements about the Company's operating environment and future performance. These statements should only be regarded as reflective of prevailing interpretations. No guarantees can be made that these statements are free from errors.